uniQure Sees Unusually High Options Volume (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) saw some unusual options trading on Thursday. Stock investors bought 24,345 call options on the company. This represents an increase of 181% compared to the typical daily volume of 8,674 call options.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Unusually heavy call‑option activity suggests some speculative buying or hedging interest that could provide short‑term upside pressure if sentiment improves. (24,345 calls traded, a ~181% increase vs. average)
• Neutral Sentiment: Recent analyst coverage roundup: several outlets published analyst takes on uniQure after volatility; read background and analyst views for context. 4QURE : 5 Analysts Assess uniQure
• Negative Sentiment: Regulatory comments from FDA leadership about the company’s rare‑disease gene‑therapy trial were cited by multiple news outlets as the immediate catalyst for the sell‑off — investors are pricing increased regulatory risk and potential delays to approval/timeline. UniQure stock tumbles on FDA comments about gene therapy trial
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff applicants for securities‑class actions alleging investor harm tied to the company’s disclosures and the FDA delay—this increases legal overhang, potential litigation costs, and reputational risk. Representative notices: Pomerantz, Rosen, Faruqi & Faruqi, Kessler Topaz, and others. Pomerantz investor alert
• Negative Sentiment: Coverage noting the class action characterizes the litigation as stemming from an FDA approval delay and a steep prior stock decline — this narrative can prolong selling pressure until regulatory clarity emerges. Class action and FDA delay coverage

Insider Activity

In related news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at approximately $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their position. The SEC filing for this sale provides additional information. 4.79% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently made changes to their positions in the company. Private Trust Co. NA bought a new position in uniQure in the third quarter valued at approximately $28,000. Jones Financial Companies Lllp boosted its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the 3rd quarter valued at $50,000. Torren Management LLC acquired a new position in shares of uniQure during the 4th quarter worth $28,000. Finally, FNY Investment Advisers LLC lifted its position in shares of uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after buying an additional 718 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ QURE opened at $17.11 on Friday. The business has a fifty day moving average price of $23.62 and a two-hundred day moving average price of $29.58. The stock has a market capitalization of $1.07 billion, a PE ratio of -3.90 and a beta of 0.66. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on QURE shares. Royal Bank Of Canada reissued an “outperform” rating on shares of uniQure in a report on Thursday. Wolfe Research initiated coverage on uniQure in a research note on Monday. They set a “peer perform” rating on the stock. Leerink Partners reduced their price target on uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research note on Monday, November 10th. William Blair reiterated a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.